Cryptococcosis Market Is Expected to Elevate to US $6.2 Bn by 2024
Albany, NY -- (SBWire) -- 04/17/2019 --Global Cryptococcosis Market: Snapshot
One of the key factors driving the global cryptococcosis market is the increasing incidence of cryptococcosis infections across the world. The number of patients suffering from cryptococcosis has been found to be on the rise at a faster rate than previously thought. The patients suffering from the fungal infection are found to be in high numbers among HIV positive patients. Consequently, the growing number of HIV patients is also spurring the demand for advanced and effective treatment for the disease. Rising initiatives by government and non-government organizations is also putting the pipeline development in the global cryptococcosis market on the fast track in many countries, especially in developed ones. However, the global cryptococcosis market is currently being affected by restraining factors such as the increased mortality among cryptococcosis infected patients, which reduces the overall scope of testing and diagnostics, and the imminent patent expiry of key drugs which will result in the large scale entry of cheaper generics.
The global cryptococcosis market was valued at US$4.12 bn in 2015 and is projected to reach US$6.27 bn by 2024, after expanding at a CAGR of 4.8% from 2016 to 2024.
Middle East and Africa HIV Numbers Boost Demand for Cryptococcosis Treatment
The global cryptococcosis market is segmented into the key regions of North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. North America accounted for the leading share on the global cryptococcosis market for 2015, due to the rising prevalence of the infection in endemic areas of the U.S., coupled with a higher penetration of healthcare services across the country. The region is projected to continue to dominate the global cryptococcosis market till 2024, a fact attributed to the rising numbers of the HIV infected population in the region, a highly structured and advanced healthcare industry, and well-defined reimbursement policies from public as well as private health insurance firms.
Request A Sample Copy @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=14984
The cryptococcosis market in the Middle East and Africa is projected to expand at a substantial growth rate owing to the contribution of Sub-Sahara African countries in terms of demand, where the count of HIV patients is exceptionally high. North America and the Middle East and Africa are projected to be highly lucrative regions in the global cryptococcosis market, while Europe, Asia Pacific, and Latin America expected to remain relatively smaller in terms of demand and growth rate.
Larger Demand for Cryptococcosis Treatment Generated from Retail Pharmacies
Based on the distribution channel, the global cryptococcosis market is segmented into hospital pharmacies, retail pharmacies, drug store, and mail order pharmacies. Retail pharmacy was the leading segment in the global market on the basis of revenue, for 2015. This segment is also expected to continue dominating the market till 2024, owing to the growing contribution of long-term medication needed for successful cryptococcosis treatment. Online purchase of drugs has been highly popular in a lot of developed economies, including the U.S. and Japan. Online pharmaceutical retailers are also generating a high volume of preference in in emerging economies such as Brazil, China, and India as well, further increasing the scope of growth for the global cryptococcosis market over the coming years.
Request Brochure @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=14984
The global cryptococcosis market is segmented on the basis of treatment, primarily into Amphotericin B, Flucytosine and Fluconazole. Amphotericin B further segmented into Amphocin, Fungizone, and other products. Flucytosine is further segmented into Ancobon and other products. Fluconazole includes Diflucan and other products. In terms of treatment, Flucytosine was the leading segment in the global cryptococcosis market in terms of revenue for 2015, driven by its large scale adoption in the U.S.
The leading players in the global cryptococcosis market so far, have included Bristol-Myers Squibb Company, Janssen Biotech, Inc. (Johnson & Johnson), Abbott Laboratories, Novartis AG, Pfizer, Inc., Valeant Pharmaceuticals, Inc., Glenmark Pharmaceuticals and Sigmapharm Laboratories LLC.
About Transparency Market Research
Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR's experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.
Each TMR syndicated research report covers a different sector – such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR's syndicated reports strive to provide clients to serve their overall research requirement.
90 State Street, Suite 700
Albany, NY 12207
USA – Canada Toll Free: 866-552-3453
Media Relations Contact
View this press release online at: http://rwire.com/1197130